Document is current
Any future updates will be listed below
-
Authors
McClements, Michelle E. https://orcid.org/0000-0002-2941-4464
Elsayed, Maram E. A. Abdalla
Major, Lauren
de la Camara, Cristina Martinez-Fernandez
MacLaren, Robert E.
-
Funding
Funding for this research was provided by:
NIHR
- License Information
-
More Information
Article History
Accepted: 30 May 2024
First Online: 2 July 2024
Declarations
:
: All authors are supported by funding from the National Institute for Health Research. The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.
: Robert E. MacLaren and Michelle E. M<sup>c</sup>Clements are co-founders of Beacon Therapeutics. Robert E. MacLaren and Michelle E. M<sup>c</sup>Clements hold consultancy agreements with Beacon Therapeutics. Robert E. MacLaren is a consultant to Scribe Therapeutics, Novartis Pharmaceuticals and Biogen Inc. Robert E. MacLaren also sits on advisory boards for the US Food and Drug Administration and the UK National Institute for Health and Care Excellence. Robert E. MacLaren and Michelle E. M<sup>c</sup>Clements are listed as inventors on retinal gene therapy patents owned by the University of Oxford. Maram E.A. Abdalla Elsayed, Lauren Major and Cristina Martinez-Fernandez de la Camara have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors provided content and performed manuscript editing.
